Jpmorgan Chase & CO Regulus Therapeutics Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Regulus Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 74,517 shares of RGLS stock, worth $608,058. This represents 0.0% of its overall portfolio holdings.
Number of Shares
74,517
Previous 190,457
60.87%
Holding current value
$608,058
Previous $300,000
56.67%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding RGLS
# of Institutions
7Shares Held
4.59MCall Options Held
0Put Options Held
25K-
Black Rock Inc. New York, NY3.97MShares$32.4 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE401KShares$3.27 Million6.25% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL85.6KShares$698,5120.0% of portfolio
-
Peak6 Investments LLC Chicago, IL60KShares$489,6000.0% of portfolio
-
Ifp Advisors, Inc0Shares$00.0% of portfolio
About Regulus Therapeutics Inc.
- Ticker RGLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,634,400
- Market Cap $119M
- Description
- Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...